8-K: Dyadic International Reports Strong Q3 2024 Results Driven by Licensing and Milestone Payments

Dyadic International announced a significant increase in revenue for Q3 2024, driven by licensing fees and milestone payments, alongside advancements in their alternative protein and pharmaceutical collaborations.

Summary

• Dyadic International reported its financial results for the third quarter of 2024, showing a substantial increase in revenue to approximately $1.96 million, compared to $397,000 in the same period last year.
• This revenue growth was primarily driven by $1 million in license revenue from Proliant and a $425,000 success fee from Inzyme.
• The company's cash position remains strong at approximately $10 million as of September 30, 2024, up from $7.3 million at the end of 2023.
• The net loss for the quarter decreased significantly to $203,000, compared to a net loss of $1.61 million in the same quarter of the previous year.
• Dyadic is advancing its C1 and Dapibus platforms across alternative proteins, human health, and animal health sectors, with multiple collaborations and product developments underway.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with significant revenue growth, reduced losses, and strong progress in collaborations and product development. The company's strong cash position and future outlook contribute to a high sentiment score.

Positives

• The company experienced a substantial increase in revenue, primarily due to licensing and milestone payments.
• Dyadic has a strong cash position of approximately $10 million.
• The net loss for the quarter significantly decreased compared to the same period last year.
• The company is making significant progress in its collaborations across various sectors, including alternative proteins and human health.
• Dyadic has successfully developed and is sampling multiple new products, including DNASE-1, recombinant transferrin, and bovine alpha-lactalbumin.
• The company is expanding its portfolio of recombinant life science proteins.

Negatives

• The cost of research and development revenue increased to approximately $396,000, compared to $106,000 in the same period last year, due to an increasing number of collaborations.
• General and administrative expenses increased slightly by 1.2% to $1.298 million.
• The company still reported a net loss of $203,000 for the quarter, although significantly reduced from the previous year.

Risks

• The company has a history of net losses.
• Market and regulatory acceptance of Dyadic's microbial protein production platforms and other technologies is not guaranteed.
• The company faces competition from alternative technologies.
• The results of nonclinical studies and clinical trials are uncertain.
• Dyadic has capital needs and is subject to changes in global economic and financial conditions.
• The company relies on information technology and is dependent on third parties.
• Government regulations and environmental, social, and governance issues pose risks.
• Intellectual property risks are present.

Future Outlook

Dyadic anticipates continued revenue growth through commercialization of alternative proteins and expects substantial midand long-term growth in human and animal health markets. The company expects to receive a final payment of $500,000 from Proliant upon meeting a defined productivity threshold and anticipates the launch of the first product in the first half of 2025.

Management Comments

• Mark Emalfarb, Dyadic's Chief Executive Officer, stated that the third quarter achievements underscore Dyadic's commitment to leveraging its proprietary Dapibus and C1 microbial protein production platforms to drive immediate and sustained revenue.
• Joe Hazelton, Dyadic's Chief Operating Officer, added that collaborations in alternative proteins and biopharmaceuticals highlight the flexibility of their platforms, allowing them to deliver consistent results across diverse applications.

Industry Context

This announcement reflects a growing trend in the biotechnology industry towards leveraging microbial platforms for efficient and scalable protein production. Dyadic's focus on both alternative proteins and biopharmaceuticals positions them to capitalize on the increasing demand for these products in various sectors.

Comparison to Industry Standards

• Dyadic's revenue growth of approximately 400% year-over-year is significantly higher than the average growth rate for many biotech companies in the same stage of development.
• The successful expression of a Mpox antigen at 4.5 g/L in 7 days using the C1 platform is a notable achievement, potentially exceeding the productivity of traditional cell culture methods like CHO cells.
• The company's collaborations with top pharmaceutical companies and leading biotech firms indicate a strong validation of their technology and potential for future growth.
• Compared to companies like Amyris and Ginkgo Bioworks, which also focus on synthetic biology and protein production, Dyadic's focus on both alternative proteins and biopharmaceuticals provides a diversified revenue stream.
• The milestone payments and licensing revenue model is similar to that of other biotech companies that focus on technology platforms, such as Codexis and Novozymes.

Stakeholder Impact

• Shareholders will likely view the increased revenue and reduced losses positively.
• Employees may benefit from the company's growth and expansion.
• Customers and partners will have access to new and improved products and technologies.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's improved financial position favorably.

Next Steps

• ViroVax is scheduled to begin preclinical studies for the Mpox vaccine in Q4 2024.
• Dyadic expects to receive a final payment of $500,000 from Proliant upon meeting a defined productivity threshold.
• The company anticipates the launch of the first product from the Proliant partnership in the first half of 2025.
• Dyadic is in discussions with various manufacturing organizations to produce a research grade DNASE-1 product with anticipation of taking pre-orders in the first quarter of 2025.
• Sampling of recombinant bovine alpha-lactalbumin is expected to begin in the late fourth quarter.
• Results of application testing for recombinant bovine transferrin for use in cell culture media for the cultured meat industry are expected in the fourth quarter.

Key Dates

Keywords

biotechnology, protein production, recombinant proteins, C1 platform, Dapibus platform, alternative proteins, vaccines, therapeutics, licensing, milestone payments, human health, animal health, financial results